> Inspire Pharmaceuticals has paid Boehringer Ingelheim $2.5 million up front to license an antihistamine to treat nasal allergies. Boehringer retains marketing rights outside of the U.S. and Canada. Report
> The University of Liverpool is contributing funds toward the creation of a new research center to focus on zoonosis, diseases like bird flu that start in animals and migrate to humans. Article
> France and The Netherlands have received EU permission to begin vaccinating bird flocks against the avian flu virus. Report
> Shares of the UK's Antisoma were on the rise after the company announced it had received EU orphan drug status for its aptamer drug AS1411 for the treatment of renal and pancreatic cancers. Report
> Shares of Antares Pharma of Exton, PA jumped after the biotech announced plans for a Phase III trial of its gel therapy for overactive bladder. Report
> India's Lupin is ending a deal with Cornerstone Biopharma for the distribution of its antibiotic Suprax in the U.S. Report
> CuraGen has released new data from its failed trial for velafermin as a treatment for cancer-related mouth sores. Report
> Rigel Pharmaceuticals of South San Francisco is planning new trials of R788 following the positive early results of a Phase I trial. Release
> The FDA has approved less restrictive labeling for Tasmar. Release
And Finally… A retired doctor from Austin filed suit against GlaxoSmithKline, saying that he lost $14 million in Las Vegas after doses of Requip and Mirapex turned him into a compulsive gambler. Article